个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Blood protein biomarkers in lung cancer

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Huang Hong[1,2] ; Yang Yongfeng[2,3] ; Zhu Yihan[1] ; Chen Hongyu[1] ; Yang Ying[2] ; Zhang Li[2,3,*2] ; Li Weimin[2,3,4,5,*1] ;
机构： [1]Institute of Clinical Pathology, Key Laboratory of Transplantation Engineering and Immunology,Ministry of Health, West China Hospital, Sichuan University, Chengdu, 610041, China [2]Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network,West China Hospital, Sichuan University, Chengdu, 610041, China [3]Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041,China [4]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University,Chengdu, 610041, China [5]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital,Chengdu, 610041, China
出处：
DOI： 10.1016/j.canlet.2022.215886
ISSN：

关键词： Tumor-associated antigen Autoantibody Exosomal protein Circulating biomarker Lung cancer diagnosis

摘要：
Lung cancer has consistently ranked first as the cause of cancer-associated mortality. The 5-year survival rate has risen slowly, and the main obstacle to improving the prognosis of patients has been that lung cancer is usually diagnosed at an advanced or incurable stage. Thus, early detection and timely intervention are the most effective ways to reduce lung cancer mortality. Tumor-specific molecules and cellular elements are abundant in circulation, providing real-time information in a noninvasive and cost-effective manner during lung cancer development. These circulating biomarkers are emerging as promising tools for early detection of lung cancer and can be used to supplement computed tomography screening, as well as for prognosis prediction and treatment response monitoring. Serum and plasma are the main sources of circulating biomarkers, and protein biomarkers have been most extensively studied. In this review, we summarize the research progress on three most common types of blood protein biomarkers (tumor-associated antigens, autoantibodies, and exosomal proteins) in lung cancer. This review will potentially guide researchers toward a more comprehensive understanding of candidate lung cancer protein biomarkers in the blood to facilitate their translation to the clinic.Copyright © 2022. Published by Elsevier B.V.

基金：
This work was supported by the National Guided Science and Technology Development Project of Sichuan Province [2020ZYD005 and 2020ZYD009]; the National Natural Science Foundation of China [82173251]; the Hospital-Enterprise Cooperative Clinical Research Innovation Project [2019HXCX04]; and the Sichuan Science and Technology Program [2020YFS0573].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
第一作者：
第一作者机构： [1]Institute of Clinical Pathology, Key Laboratory of Transplantation Engineering and Immunology,Ministry of Health, West China Hospital, Sichuan University, Chengdu, 610041, China [2]Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network,West China Hospital, Sichuan University, Chengdu, 610041, China
共同第一作者：
通讯作者：
通讯机构： [2]Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network,West China Hospital, Sichuan University, Chengdu, 610041, China [3]Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041,China [4]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University,Chengdu, 610041, China [5]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital,Chengdu, 610041, China [*1]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, China. [*2]Institute of Respiratory Health, Precision Medicine Center, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, China.
推荐引用方式(GB/T 7714)：
Huang Hong,Yang Yongfeng,Zhu Yihan,et al.Blood protein biomarkers in lung cancer[J].Cancer letters.2022,215886.doi:10.1016/j.canlet.2022.215886.
APA：
Huang Hong,Yang Yongfeng,Zhu Yihan,Chen Hongyu,Yang Ying...&Li Weimin.(2022).Blood protein biomarkers in lung cancer.Cancer letters,,
MLA：
Huang Hong,et al."Blood protein biomarkers in lung cancer".Cancer letters .(2022):215886

相关文献

[1]Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization [2]Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients [3]Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. [4]Granzyme B in circulating CD8+T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders [5]High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer [6]CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer. [7]Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. [8]Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer [9]Metabolomics Analysis and Diagnosis of Lung Cancer: Insights from Diverse Sample Types [10]Optimal communication associated with lower risk of acute traumatic stress after lung cancer diagnosis.

资源点击量：43378 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号